Back to search results

CARE Tool Study for Gynecologic, Prostate, Lung, and Colorectal Cancers

This study is testing a web-based tool called the CARE Tool. This tool gives you information about cancer care costs, health insurance, and resources to help with these costs. The study aims to help patients with gynecologic, prostate, lung, or colorectal cancer understand and manage the financial side of their treatment. You might be eligible if you are 18 years or older and have one of these cancer types. Researchers will measure how well the CARE Tool helps with your financial understanding and ability to talk about costs. The current status of this study is unclear.

Study design
This is a multi-site randomized trial, meaning participants will be assigned by chance to receive either the CARE Tool or standard financial education resources. The study plans to enroll 430 participants.
What's involved
Your participation will involve completing an initial survey and a follow-up survey, with a total estimated time of 3 months.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for approximately 3 months after completing the initial survey.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07296887

CARE Tool Study Aim 3

Recruiting
NAAges 18+InterventionalHealth services
Washington University School of Medicine
~430 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:Financial education informationCARE ToolCARE Tool Training

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient's comprehensive score for financial toxicity (COST)
Measured over Completion of initial survey to completion of follow up survey (total estimated time is 3 months)
+2 more outcomes measured

Conditions

Gynecologic Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer

Explore related trials

Colorectal CarcinomaLung CarcinomaMalignant Female Reproductive System NeoplasmProstate Carcinoma

Where it's being run

3 sites across 2 states
Missouri2
Illinois1

Study leadership

  • Ashley Housten, OTD, MSCI, OTR/L · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Ashley Housten, OTD, MSCI, OTR/L
[email protected]
314-454-7958
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 and over
Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months
Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
Self-reported ability to read and speak English

Exclusion

Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
Do not treat patients for gynecologic, prostate, lung, or colorectal cancer
Under the age of 18
Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment
Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
Cannot give consent due to cognitive or emotional barriers

What this trial measures

  • Patient's comprehensive score for financial toxicity (COST)Completion of initial survey to completion of follow up survey (total estimated time is 3 months)

    COST will be calculated by the sum of 11-items according to the validated measure. The items are scored on a 5-point Likert scale as follows: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, and 4-Very much. Total possible range is 0-44 and the lower the score indicates greater financial toxicity. Scores will be summarized using means and 95% confidence intervals. Changes between timepoints will be analyzed by a two-sample t-test.

  • Patient's score of self-efficacy for communicating about care costs measured with the Decision Self-Efficacy ScaleCompletion of initial survey to completion of follow up survey (total estimated time is 3 months)

    The measure of self-efficacy for communicating about care costs is adapted from the validated tool Decision Self-Efficacy Scale. The Decision Self-Efficacy Scale measures self-confidence or belief in one's abilities in decision making, including shared decision making. Three-items from the Decision Self-Efficacy Scale will be used to measure self-efficacy for communicating about care costs. The three items will be measured by a 3-point Likert scale as follows: 0-Not Confident, 2-A Little Confident, and 4-A lot confident. A higher score indicates greater self-efficacy in decision making. The total score will be calculated according to the validated measure. Scores will be summarized using means and 95% confidence intervals. Changes between timepoints will be analyzed by a two-sample t-test.

  • Patient's health insurance literacy measure (HILM) scoreCompletion of initial survey to completion of follow up survey (total estimated time is 3 months)

    HILM score is calculated from a 6-item questionnaire according to the validated measure. Each item is measured by a 4-point Likert scale as follows: 1-Not at all confident, 2-Slightly confident, 3-Moderately confident, and 4-Very confident. Total possible range is 0-100 where 0 represents the lowest possible health insurance literacy level (more difficulty navigating insurance) and 100 represents the highest (more confidence in choosing/using insurance). Scores will be summarized using means and 95% confidence intervals. Changes between timepoints will be analyzed by a two-sample t-test.